Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Determining the Mutational Landscape of Waldenström's Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström's Macroglobulinemia
Philipp Nakov, Daniela Drandi, Lisa Kaiser, Dajana Kaszynski, Alexander Grunenberg, Jasmin Mark, E Runge, Meletios A Dimopoulos, Efstathios Kastritis, Tina Bagratuni, Christian Buske, Christiane Pott, Simone Ferrero, Mouhamad Khouja (2024). Determining the Mutational Landscape of Waldenström's Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström's Macroglobulinemia. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-204645.
Article43 days agoBortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial (<i>ECWM-2</i>) of the <i>European Consortium for Waldenström's Macroglobulinemia</i>
Christian Buske, Efstathios Kastritis, Alexander Grunenberg, Andreas Viardot, Dajana Kaczynski, Heike Mund, Katja Gutmair, Matthias Zingerle, Paul Duewel, Susanne Saußele, Björn Schöttker, Ullrich Graeven, Martin Dreyling, Andrea Kerkhoff, Thomas Weber, Holger Hebart, Ralf Ulrich Trappe, Lisa Kaiser, E Runge, Jasmin Mark, Simone Ferrero, Daniela Drandi, Falko Fend, Irina Bonzheim, Eva Hoster, Jens Dreyhaupt, Meletios A Dimopoulos (2024). Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial (<i>ECWM-2</i>) of the <i>European Consortium for Waldenström's Macroglobulinemia</i>. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-200604.
Article43 days agoBortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial (<i>ECWM-2</i>) of the <i>European Consortium for Waldenström's Macroglobulinemia</i>
Christian Buske, Efstathios Kastritis, Alexander Grunenberg, Andreas Viardot, Dajana Kaczynski, Heike Mund, Katja Gutmair, Matthias Zingerle, Paul Duewel, Susanne Saußele, Björn Schöttker, Ullrich Graeven, Martin Dreyling, Andrea Kerkhoff, Thomas Weber, Holger Hebart, Ralf Ulrich Trappe, Lisa Kaiser, E Runge, Jasmin Mark, Simone Ferrero, Daniela Drandi, Falko Fend, Irina Bonzheim, Eva Hoster, Jens Dreyhaupt, Meletios A Dimopoulos (2024). Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial (<i>ECWM-2</i>) of the <i>European Consortium for Waldenström's Macroglobulinemia</i>. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-200604.
Article43 days ago